MRA Advisory Group’s holdings in Amgen were worth $1,541,000 at the end of the most recent reporting period. Finally, Ares Financial Consulting LLC bought a new position in shares of Amgen during the fourth quarter worth about $34,000. Oppenheimer boosted their price target on Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a report on Wednesday. Amgen Stock Climbs as Drug Growth Outruns Obesity SetbackManagement now expects fiscal-year earnings of $22.30 to $23.50 per share, supported by growth in cardiovascular, bone-health and rare-disease medicines. BMO Capital Markets Boosts Amgen Price Target to $450BMO Capital Markets raised its target to $450, while UBS and TD Cowen set targets of $440 and $452, respectively.